The regulatory pathway for Rituximab Biosimilars Market has matured significantly, with multiple products now approved across major jurisdictions. The U.S. Food and Drug Administration (FDA) has approved several rituximab biosimilars since 2017, including Celltrion’s Truxima, Pfizer’s Ruxience, and Amgen’s Riabni. These approvals have not only validated the biosimilar development pathway but have also expanded treatment options for patients with B-cell malignancies and autoimmune disorders.

A landmark development occurred on June 12, 2025, when Celltrion, Amgen, and Pfizer each received FDA approval for an additional indication for their rituximab biosimilars: the treatment of moderate to severe pemphigus vulgaris (PV), a rare autoimmune blistering disease. This approval granted Celltrion its fifth adult indication for the CD20-targeting therapy, bringing Truxima nearly in line with Rituxan’s label, with only pediatric lymphoma and leukemia still out of reach. With this addition, Truxima now covers non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and PV.

Amgen’s Riabni achieved an even more significant milestone: it now mirrors Rituxan’s label across all approved uses, including pediatric patients with GPA and MPA. This makes Riabni the first rituximab biosimilar to achieve full label alignment with the originator. Pfizer’s Ruxience, while also receiving the PV approval, continues to trail behind, missing both CLL and RA indications, making it the only biosimilar without full adult coverage.

The regulatory landscape in Europe is equally active. The European Medicines Agency (EMA) was the first to approve rituximab biosimilars, with CT-P10 (Truxima) receiving approval in 2017 for all indications of the reference biological drug. This was followed by GP2013 (Rixathon) for rheumatoid arthritis and Ruxience for lymphoma and leukemia. More recently, Dr. Reddy’s Laboratories received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) for its proposed biosimilar DRL_RI (ITUXREDI), recommending its launch in European markets. The intended indications mirror those of MabThera, covering NHL, CLL, RA, GPA, MPA, and PV.

In a groundbreaking move, the FDA accepted a monoclonal antibody biosimilar application without requiring clinical efficacy studies, signaling a potential shift toward more streamlined approval pathways based on robust analytical and pharmacokinetic data. This could accelerate future biosimilar development, further intensifying competition in the rituximab biosimilars market. As regulatory frameworks continue to evolve and expand, patient access to these cost-effective alternatives will only improve, driving market growth through 2035.